About this Journal Submit a Manuscript Table of Contents
Gastroenterology Research and Practice
Volume 2012 (2012), Article ID 378064, 9 pages
http://dx.doi.org/10.1155/2012/378064
Review Article

Pharmacokinetics of the Perioperative Use of Cancer Chemotherapy in Peritoneal Surface Malignancy Patients

1Department of Surgical Oncology, Oost-Limburg Hospital, Schiepse Bos 6, 3600 Genk, Belgium
2Department of Biochemistry, Faculty of Medicine, University Hasselt, 3590 Diepenbeek, Belgium
3Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA

Received 10 March 2012; Accepted 23 April 2012

Academic Editor: Yan Li

Copyright © 2012 K. Van der Speeten et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. The peritoneal surface is an acknowledged locoregional failure site of abdominal malignancies. Previous treatment attempts with medical therapy alone did not result in long-term survival. During the last two decades, new treatment protocols combining cytoreductive surgery with perioperative intraperitoneal and intravenous cancer chemotherapy have demonstrated very encouraging clinical results. This paper aims to clarify the pharmacologic base underlying these treatment regimens. Materials and Methods. A review of the current pharmacologic data regarding these perioperative chemotherapy protocols was undertaken. Conclusions. There is a clear pharmacokinetic and pharmacodynamic rationale for perioperative intraperitoneal and intravenous cancer chemotherapy in peritoneal surface malignancy patients.